AbbVie’s blockbuster drug Skyrizi gets FDA nod for treating Crohn’s disease

AbbVie drug Skyrizi is now approved for Crohn’s disease, making it the first treatment for the disorder that addresses a particular protein associated with inflammation. In other drug decision news, the Rhythm Pharmaceuticals product Imcivree added the rare disease Bardet-Beidl syndrome as a new approved indication.

Leave a Reply

Your email address will not be published. Required fields are marked *